IQVIA (NYSE:IQV) Releases FY 2024 Earnings Guidance

by · The Cerbat Gem

IQVIA (NYSE:IQV – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 11.100-11.200 for the period, compared to the consensus EPS estimate of 11.210. The company issued revenue guidance of $15.4 billion-$15.4 billion, compared to the consensus revenue estimate of $15.5 billion. IQVIA also updated its FY24 guidance to $11.10-11.20 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Robert W. Baird reduced their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. BTIG Research decreased their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday. Finally, JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $261.24.

View Our Latest Report on IQV

IQVIA Trading Up 1.6 %

Shares of IQV stock traded up $3.34 on Friday, hitting $209.16. The stock had a trading volume of 1,791,887 shares, compared to its average volume of 1,125,496. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85. The firm has a market capitalization of $38.13 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.01 and a beta of 1.51. The company’s 50 day moving average price is $234.31 and its 200-day moving average price is $229.74. IQVIA has a 1 year low of $181.03 and a 1 year high of $261.73.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also